Global Antibiotics Market Report 2023: Featuring Bayer, Fujisawa Pharmaceutical, GlaxoSmithKline, Merck and More

Rhea-AI Summary

The global antibiotics market is expected to grow steadily in the coming years due to the increasing prevalence of bacterial infections and the emergence of multi-drug resistant bacteria. The market is driven by the need for novel antibiotics and extensive research and development initiatives. North America and Asia-Pacific currently dominate the market. Key players in the market include ABAC Therapeutics, Bayer, Bristol Myers Squibb, GlaxoSmithKline, Merck, Pfizer, and Wockhardt.

Positive

• The antibiotics market is anticipated to grow at a steady pace in the coming years, driven by the increasing need for novel antibiotics and extensive research and development initiatives by industry players.

Negative

• None.

DUBLIN, April 27, 2023 /PRNewswire/ -- The "Global Antibiotics Market - Distribution by Type of Drug Class, Target Disease Indication, Type of Therapy (Monotherapies and Combination Therapies), Route of Administration and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035" report has been added to  ResearchAndMarkets.com's offering.

The report features an extensive study of the current market landscape and future opportunity for the players involved in the development of antibiotics. The report answers many key questions related to this domain.

Bacterial infections are known to be one of the leading causes of deaths, worldwide. In fact, infections caused by bacteria are responsible for every one out of eight deaths, globally. This can be attributed to the fact that majority of the pathogenic bacteria have developed resistance against the commonly prescribed therapies.

In addition, as per the Centers for Disease Control and Prevention (CDC), the annual healthcare cost associated with treatment of infections caused by six multi-drug resistant bacteria is estimated to be more than USD 4.6 billion in the US. Antibiotics (chemical substances derived from the biological sources or produced chemically) are extensively being used for the prevention / treatment of various bacterial infections.

Over the past few years, a number of novel broad-spectrum (antibiotics that provide therapeutic effects against a wide range of bacteria) and narrow spectrum (antibiotics that provide therapeutic effects against specific bacterial strains only) antibiotic therapies, targeting a myriad of bacterial infections (in alphabetical order), including anthrax, botulism, cholera, gonorrhea, meningitis, pneumonia, tetanus, tuberculosis, and syphilis, have received approval from various regulatory authorities, globally.

However, the antibiotic drug development is currently fraught with several challenges, including emergence of drug-resistant bacteria and concerns related to safety and efficacy of these therapies.

In order to address the aforementioned concerns, several industry stakeholders have been actively leading the efforts for research and development of effective and safe antibiotics. In addition, over the years, several regulatory organizations, including the World Health Organization (WHO), CDC and United States Food and Drug Administration (USFDA) have undertaken various initiatives to not only promote the correct usage of antibiotics but also support the players engaged in this industry.

The continuous efforts of both industry and non-industry players as well as regulatory organizations, combined with the increasing patient population, are expected to be the key drivers for growth in the antibiotics market in the coming years.

Need for Novel Antibiotics Targeting Multi-drug Resistant Bacterial Infections

Over the years, due to overuse of antibiotics, bacterial strains have developed resistance to most of the commercially available antibiotics, a phenomenon known as antibiotic / antimicrobial resistance (AMR). Notably, in November 2021, the World Health Organization (WHO) declared AMR as one of the top ten threats for the global public health standards. In order to address the aforementioned challenge, drug developers are currently evaluating various novel antibiotics. These novel antibiotics belong to previously unexplored drug classes that can target new pathways to inhibit bacterial growth. In addition, some of these therapies are being evaluated to overcome the challenges of cross resistance (commonly observed in currently available antibiotics).

Current Market Landscape of Antibiotics

Since 1980, close to 50 unique antibiotics have been approved for the prevention / treatment of various infections caused by gram negative as well as gram positive bacteria. Further, in the last eight years, developers have received approvals for more than 25 novel antibiotics intended for the treatment of multiple infectious diseases. It is worth highlighting that over 150 antibiotics are currently being evaluated in more than 1,720 trials across different stages of preclinical / clinical development, either as monotherapies or combination therapies. Majority of these clinical-stage antibiotics are being developed for the treatment of infections caused by members of Enterobacteriaceae family.

Partnership and Collaboration Trends in Antibiotics Domain

Currently, several partnerships have been inked by various industry and non-industry players engaged in the development of antibiotics. It is worth highlighting that 30% of these partnerships were inked in 2022. Majority of such deals are focused on joint development of antibiotics, followed by agreements signed for the purpose of research and development, product development and commercialization of antibiotics.

Impact of COVID-19 on the Antibiotics Industry

It is worth highlighting that a significant surge has been observed in the use of antibiotics, since 2020. This can be attributed to the fact that various antibiotic generics, namely azithromycin, ceftriaxone, moxifloxacin and meropenem, were used extensively in the initial phase of the pandemic.

However, the COVID-19 pandemic caused the disruption of the supply chain of antibiotics. Hence, in order to address the increasing demand as well as overcome the aforementioned supply chain-related disruption, a number of developers based in North America and Europe either expanded their facilities or established new facilities for the manufacturing of antibiotics.

Key Drivers for the Antibiotics Market

The increasing prevalence of various infections caused by both gram positive and gram-negative bacteria is one of the key drivers for the antibiotics market. In addition, emergence of multi-drug resistant bacteria, current unmet need for novel antibiotics and extensive research and development initiatives by industry players are expected to drive the growth in antibiotics market in the coming years.

Market Size of Antibiotics

Driven by the increasing need for novel antibiotics, along with growing development pipeline and encouraging clinical trial results, the antibiotics market is anticipated to grow at a steady pace in the coming years. Specifically, in terms of target disease indication, the market is anticipated to be driven by therapies being developed for the treatment of urinary tract infections, and dermatological infections. Additionally, it is worth highlighting that majority of the current market share is captured by players based in North America and Asia-Pacific.

Key Players in the Antibiotics Market

Examples of the key players in this domain (the complete list of players is available in the full report) include ABAC Therapeutics, Bayer, Biocidium Biopharmaceuticals, Blacksmith Medicines, Bristol Myers Squibb, Crestone, Daiichi Sankyo, Debiopharm, Fedora Pharmaceuticals, Fujisawa Pharmaceutical, GlaxoSmithKline, Helperby Therapeutics, Madam Therapeutics, Melinta Therapeutics, Meiji Seika Pharma, MicuRx Pharmaceuticals, Merck, Pfizer, Qpex Biopharma, RedHill Biopharma, Selmod, Sequella, Sinovent, Spero Therapeutics and Wockhardt.

Scope of the Report

The study presents an in-depth analysis of the various firms / organizations that are engaged in this domain, across different segments.

The study presents detailed information on current market landscape and future opportunities of various stakeholders engaged in this domain. Amongst other elements, the report includes:

• An executive summary of the insights captured during our research, offering a high-level view on the current state of the global antibiotics market and its likely evolution in the mid-to-long term.
• A general introduction to antibiotics, along with information on their characteristics and advantages, and classification (based on chemical structure, mode of action, range of activity and source). In addition, the chapter highlights details on the history of antibiotics, innovations related to antibiotics, mechanism of action of antibiotics and challenges associated with their use. Further, it concludes with a discussion on the future perspectives in this domain.
• A detailed assessment of the overall market landscape of approved antibiotic generics, based on several relevant parameters, such as year of approval, region(s) of approval, type of antibiotic (based on chemical structure and drug class), mechanism of action (alteration of cell membranes, cell wall synthesis inhibition, mycolic acid synthesis inhibition, nucleic acid synthesis inhibition, protein synthesis inhibition and RNA polymerase inhibition), spectrum of activity (broad spectrum, extended spectrum and narrow spectrum), type of target bacteria(s) (gram negative and gram positive), target bacterial strain(s), target diseases indication(s), nature of source (semi-synthetic and synthetic), type of therapy (combination therapy and monotherapy), route(s) of administration (intramuscular, intravenous, oral, topical and others / unspecified), dosage form(s) (capsules, creams, liquids, powder, tablets and others), and type of patient population (based on age and gender). In addition, it provides an in-depth analysis on the developers engaged in the development of antibiotic generics, based on their year of establishment, company size, location of headquarters and most active players (in terms of number of approved generics).
• A detailed assessment of the overall market landscape of approved antibiotic brands, based on several relevant parameters.
• A detailed assessment of the overall market landscape of clinical-stage antibiotics, based on several relevant parameters.
• Elaborate profiles of key players engaged in the development of antibiotics.
• A detailed analysis of partnerships inked between stakeholders engaged in this domain, since 2017, based on several relevant parameters, such as year of partnership, type of partnership (acquisitions, commercialization agreements, distribution agreements, joint development agreements, licensing agreements, manufacturing agreements, product development agreements, product development and commercialization agreements, research and development agreements, technology utilization agreements and others), type of partner, company size, most active players (in terms of number of partnerships)., and regional distribution of partnership activity in this domain.
• An analysis of completed and ongoing clinical studies related to antibiotics, based on several relevant parameters, such as trial registration year, trial status, trial phase, type of patient population (based on gender), key focus areas, type of sponsor, geography and most active industry and non-industry players (in terms of number of trials).
• An insightful analysis, highlighting the key opinion leaders (KOLs) investigating clinical trials related to antibiotics, based on several relevant parameters, such as type of KOL, qualification, type of organization, affiliated organization, geographical location of KOLs and target disease indication(s). In addition, the chapter highlights the most prominent KOLs, based on our proprietary and third-party scoring criteria.
• An insightful success protocol analysis of recently approved antibiotics, based on several relevant parameters, such as dosing frequency, drug efficacy, geographical reach, inter-class competition, intra-class competition, t innovation feature, price, prevalence, route of administration, spectrum of activity, type of therapy and type of target bacteria.

Frequently Asked Questions

Question 1: What are antibiotics?

Answer: Antibiotics are chemical substances that are either derived from biological sources or produced chemically. These chemicals are used for the prevention / treatment of various bacterial infections.

Question 2: What are the top 10 antibiotics?

Answer: The top 10 antibiotics (in alphabetical order) are amoxicillin, azithromycin, cephalexin, ciprofloxacin, clavulanate, clindamycin, doxycycline, levofloxacin, metronidazole, and sulfamethoxazole.

Question 3: How many novel antibiotics have been approved for the treatment of bacterial infections over the years?

Answer: Since 2016, more than 25 antibiotics have been approved by various regulatory organizations, across the globe.

Question 4: How many companies develop antibiotics?

Answer: 50 industry players are currently engaged in the evaluation and development of over 150 potential antibiotics for the treatment of patients suffering from a wide array of bacterial infections.

Question 5: What are the key types of partnerships and collaborations signed in the antibiotics industry?

Answer: Currently, research and development agreements, joint development agreements and product development and commercialization agreements are the common types of partnerships inked by developers that are currently focused on the development of antibiotics.

Question 6: What is the growth rate of antibiotics market?

Answer: The antibiotics market is expected to grow at a steady rate in the period 2023-2035.

Question 7: Which region has the highest growth rate in the antibiotics market?

Answer: Asia-Pacific is expected to grow at the highest rate, over the period 2023-2035.

Question 8: Which segment, in terms of type of drug class, accounts for the largest share within the antibiotics market?

Answer: At present, aminoglycoside accounts for the largest market share, in terms of revenues, within the antibiotics market.

For more information about this report visit https://www.researchandmarkets.com/r/6vi1sg

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com 
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/global-antibiotics-market-report-2023-featuring-bayer-fujisawa-pharmaceutical-glaxosmithkline-merck-and-more-301809494.html

SOURCE Research and Markets

FAQ

What is driving the growth of the antibiotics market?

The growth of the antibiotics market is driven by the increasing prevalence of bacterial infections, emergence of multi-drug resistant bacteria, and the need for novel antibiotics.

Which regions dominate the antibiotics market?

North America and Asia-Pacific currently dominate the antibiotics market.

Who are the key players in the antibiotics market?

Key players in the antibiotics market include ABAC Therapeutics, Bayer, Bristol Myers Squibb, GlaxoSmithKline, Merck, Pfizer, and Wockhardt.

What is the current market landscape of antibiotics?

There are close to 50 unique antibiotics approved for the prevention/treatment of various infections. Over 150 antibiotics are currently being evaluated in more than 1,720 trials.